iSpecimen Inc. Announces Closing of $4 Million Underwritten Offering
iSpecimen (NASDAQ:ISPC), an online marketplace for biospecimens, has completed its previously announced underwritten public offering, raising $4 million in gross proceeds. The offering consisted of 5,714,283 shares of common stock (or pre-funded warrants) priced at $0.70 per share.
The Company plans to allocate $1.5 million for marketing services through IR Agency LLC, $1 million for an initial milestone payment to Sales Stack Solutions Corp., with the remaining funds designated for working capital and general corporate purposes. WestPark Capital, Inc. served as the Sole Book-Runner for this firm commitment offering.
["Secured $4 million in gross proceeds from the offering", "Clear allocation plan for the raised funds including marketing and strategic initiatives"]iSpecimen (NASDAQ:ISPC), un marketplace online per biospecimen, ha completato la sua offerta pubblica sottoscritta precedentemente annunciata, raccogliendo 4 milioni di dollari di proventi lordi. L'offerta consisteva in 5.714.283 azioni ordinarie (o warrant pre-finanziati) al prezzo di 0,70 dollari per azione.
L'azienda prevede di destinare 1,5 milioni di dollari a servizi di marketing tramite IR Agency LLC, 1 milione di dollari come pagamento iniziale a Sales Stack Solutions Corp., mentre i fondi rimanenti saranno impiegati per il capitale circolante e scopi aziendali generali. WestPark Capital, Inc. ha agito come unico bookrunner per questa offerta a impegno fermo.
iSpecimen (NASDAQ:ISPC), un mercado en l铆nea de biospec铆menes, ha completado su oferta p煤blica suscrita previamente anunciada, recaudando 4 millones de d贸lares en ingresos brutos. La oferta consisti贸 en 5.714.283 acciones comunes (o warrants prefinanciados) a un precio de 0,70 d贸lares por acci贸n.
La compa帽铆a planea destinar 1,5 millones de d贸lares para servicios de marketing a trav茅s de IR Agency LLC, 1 mill贸n de d贸lares para un pago inicial a Sales Stack Solutions Corp., y los fondos restantes se destinar谩n a capital de trabajo y prop贸sitos corporativos generales. WestPark Capital, Inc. actu贸 como 煤nico bookrunner para esta oferta con compromiso firme.
iSpecimen (NASDAQ:ISPC)鞚� 靸濍 響滊掣鞚� 鞙勴暅 鞓澕鞚� 毵堨紦頂岆爤鞚挫姢搿�, 鞚挫爠鞐� 氚滍憸頃� 鞚胳垬 瓿惦毳� 鞕勲頃橃棳 400毵� 雼煬鞚� 齑� 靾橃澋鞚� 頇曤炒頄堨姷雼堧嫟. 鞚措矆 瓿惦電� 5,714,283欤�鞚� 氤错喌欤�(霕愲姅 靹犽偐 鞗岆煱韸�)搿�, 欤茧嫻 0.70雼煬鞐� 臧�瓴╈澊 毂呾爼霅橃棃鞀惦媹雼�.
須岇偓電� IR Agency LLC毳� 韱淀暅 毵堨紑韺� 靹滊箘鞀れ棎 150毵� 雼煬, Sales Stack Solutions Corp.鞐� 雽�頃� 齑堦赴 毵堨澕鞀ろ啢 歆�旮夑笀鞙茧 100毵� 雼煬毳� 氚办爼頃� 瓿勴殟鞚措┌, 雮橂ǜ歆� 鞛愱笀鞚� 鞖挫爠鞛愲掣 氚� 鞚茧皹 旮办梾 氇╈爜鞐� 靷毄頃� 鞓堨爼鞛呺媹雼�. WestPark Capital, Inc.臧� 鞚措矆 頇曥爼 鞚胳垬 瓿惦鞚� 雼弲 攵侂煬雱� 鞐暊鞚� 毵§晿鞀惦媹雼�.
iSpecimen (NASDAQ:ISPC), une place de march茅 en ligne pour les biosp茅cimens, a finalis茅 son offre publique souscrite pr茅c茅demment annonc茅e, levant 4 millions de dollars de produits bruts. L'offre comprenait 5 714 283 actions ordinaires (ou bons de souscription pr茅financ茅s) au prix de 0,70 dollar par action.
La soci茅t茅 pr茅voit d'allouer 1,5 million de dollars aux services marketing via IR Agency LLC, 1 million de dollars pour un paiement initial 脿 Sales Stack Solutions Corp., et les fonds restants seront destin茅s au fonds de roulement et aux besoins g茅n茅raux de l'entreprise. WestPark Capital, Inc. a agi en tant que teneur de livre unique pour cette offre ferme.
iSpecimen (NASDAQ:ISPC), ein Online-Marktplatz f眉r Biospezimen, hat sein zuvor angek眉ndigtes 枚ffentliches Angebot mit Underwriting abgeschlossen und dabei 4 Millionen US-Dollar Bruttoerl枚s erzielt. Das Angebot bestand aus 5.714.283 Aktien des Stammkapitals (oder vorfinanzierten Warrants) zu einem Preis von 0,70 US-Dollar pro Aktie.
Das Unternehmen plant, 1,5 Millionen US-Dollar f眉r Marketingdienstleistungen 眉ber IR Agency LLC zu verwenden, 1 Million US-Dollar als anf盲ngliche Meilensteinzahlung an Sales Stack Solutions Corp. zu leisten, und die verbleibenden Mittel f眉r Betriebskapital und allgemeine Unternehmenszwecke einzusetzen. WestPark Capital, Inc. fungierte als alleiniger Bookrunner f眉r dieses verbindliche Angebot.
- None.
- Significant dilution due to issuance of 5,714,283 new shares
- Low offering price of $0.70 per share indicates potential market weakness
Insights
iSpecimen's $4M offering at $0.70/share represents significant dilution with funds mainly directed to marketing and sales efforts.
This $4 million offering by iSpecimen represents a substantial capital raise relative to the company's size, but comes with significant shareholder dilution. The offering price of
Looking at the use of proceeds, the allocation is particularly revealing:
This allocation suggests iSpecimen is prioritizing marketing and sales infrastructure over direct R&D or platform development. The company's biospecimen marketplace business model requires both healthcare provider partnerships and scientific customers, making these investments potentially strategic for expanding market reach.
However, the firm commitment underwriting structure by WestPark Capital indicates the offering had guaranteed placement, which was likely necessary given market conditions. The low per-share price of
WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (鈥渋Specimen鈥� or the 鈥淐ompany鈥�), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of
The Company intends to use the net proceeds from the Offering to pay
The Offering was conducted on a firm commitment basis. WestPark Capital, Inc. acted as the Sole Book-Runner in connection with the Offering.
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-286958), which was declared effective by the Securities and Exchange Commission (the 鈥淪EC鈥�) on July 23, 2025. The Offering is being made only by means of a written prospectus that forms a part of the registration statement. A final prospectus relating to the Offering has been filed with the SEC. Copies of the final prospectus relating to the Offering may be obtained from WestPark Capital, Inc., 1800 Century Park East, Suite 220, Los Angeles, CA 90077, tel: 310-203-2919,听e-mail:听听and are available on the SEC鈥檚 website.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit听.听
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 鈥渇orward-looking statements.鈥� These statements include, but are not limited to, statements concerning the development of our company. The words 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渢arget,鈥� 鈥渨ill,鈥� 鈥渨ould鈥� and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including the uncertainty regarding future commercial success; risks and uncertainties associated with market conditions and the Company鈥檚 ability to satisfy the closing conditions related to the Offering. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 鈥淩isk Factors鈥� section of the Company鈥檚 Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
For further information, please contact:听
Investor Contact听
KCSA Strategic Communications听
Phil Carlson听
听
FAQ
What is the size and price of iSpecimen's (ISPC) July 2025 public offering?
How will iSpecimen (ISPC) use the proceeds from its $4M offering?
Who was the underwriter for iSpecimen's (ISPC) July 2025 offering?
What type of company is iSpecimen (ISPC)?
What was the registration status of iSpecimen's (ISPC) offering?
